MA49378A - Méthode de traitement de la thrombocytopénie immunitaire - Google Patents

Méthode de traitement de la thrombocytopénie immunitaire

Info

Publication number
MA49378A
MA49378A MA049378A MA49378A MA49378A MA 49378 A MA49378 A MA 49378A MA 049378 A MA049378 A MA 049378A MA 49378 A MA49378 A MA 49378A MA 49378 A MA49378 A MA 49378A
Authority
MA
Morocco
Prior art keywords
treatment
immune thrombocytopenia
thrombocytopenia
immune
Prior art date
Application number
MA049378A
Other languages
English (en)
Inventor
Claus Peter Kiessling
Grant Langdon
Rocio Lledo-Garcia
Ute Massow
Rose Gunter Snipes
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709554.8A external-priority patent/GB201709554D0/en
Priority claimed from GBGB1718589.3A external-priority patent/GB201718589D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA49378A publication Critical patent/MA49378A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049378A 2017-06-15 2018-06-15 Méthode de traitement de la thrombocytopénie immunitaire MA49378A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709554.8A GB201709554D0 (en) 2017-06-15 2017-06-15 Method of treatment
GBGB1718589.3A GB201718589D0 (en) 2017-11-10 2017-11-10 Method of treatment

Publications (1)

Publication Number Publication Date
MA49378A true MA49378A (fr) 2020-04-22

Family

ID=62684788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049378A MA49378A (fr) 2017-06-15 2018-06-15 Méthode de traitement de la thrombocytopénie immunitaire

Country Status (16)

Country Link
US (1) US20200140548A1 (fr)
EP (1) EP3638305A1 (fr)
JP (1) JP2020523419A (fr)
KR (1) KR20200018643A (fr)
CN (1) CN110785186A (fr)
AU (1) AU2018285577A1 (fr)
BR (1) BR112019026694A2 (fr)
CA (1) CA3066298A1 (fr)
CL (1) CL2019003673A1 (fr)
CO (1) CO2019014525A2 (fr)
IL (1) IL271248A (fr)
MA (1) MA49378A (fr)
MX (1) MX2019015065A (fr)
RU (1) RU2020100880A (fr)
SG (1) SG11201911832PA (fr)
WO (1) WO2018229249A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637929A1 (fr) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anticorps anti-fcrn utilises dans le traitement d'etats auto/allo-immuns
WO2009131702A2 (fr) * 2008-04-25 2009-10-29 Dyax Corp. Protéines de liaison au récepteur fc
AU2012262007B2 (en) * 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
PL3137504T3 (pl) * 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
WO2018229249A1 (fr) 2018-12-20
CN110785186A (zh) 2020-02-11
KR20200018643A (ko) 2020-02-19
CO2019014525A2 (es) 2020-04-24
CL2019003673A1 (es) 2020-07-17
SG11201911832PA (en) 2020-01-30
EP3638305A1 (fr) 2020-04-22
RU2020100880A3 (fr) 2021-11-10
CA3066298A1 (fr) 2018-12-20
RU2020100880A (ru) 2021-07-15
BR112019026694A2 (pt) 2020-06-23
JP2020523419A (ja) 2020-08-06
US20200140548A1 (en) 2020-05-07
IL271248A (en) 2020-01-30
MX2019015065A (es) 2020-08-03
AU2018285577A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
PL3417724T3 (pl) Sposób przetwarzania papierosów podgrzewanych
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
EP3500264A4 (fr) Méthode de traitement de l'oesophagite éosinophile
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3500289A4 (fr) Procédés de traitement de la trachéobronchomalacie
EP3341080A4 (fr) Méthode de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3261641A4 (fr) Traitement de la pancréatite
EP3820461A4 (fr) Méthode de traitement du cancer
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
EP3307280A4 (fr) Traitement de dysfonction sexuelle
MA41462A (fr) Méthode de traitement de maladies
EP3448365A4 (fr) Méthode de traitement de la constipation
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3436080A4 (fr) Méthode de préparation de sperme
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3867280A4 (fr) Méthodes de traitement de la polyarthrite rhumatoïde
EP3440107A4 (fr) Méthode de traitement de l'athérosclérose
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
MA42930A (fr) Traitement de maladies neurodégénératives
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3398613A4 (fr) Méthode de traitement de la leucémie par effet de reprogrammation
EP3703707A4 (fr) Méthode de traitement de troubles de type acide-base